Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1972 Nov 11;4(5836):322–324. doi: 10.1136/bmj.4.5836.322

Changes in Human Drug Metabolism after Long-term Exposure to Hypnotics

I H Stevenson, Margaret Browning, J Crooks, K O'Malley
PMCID: PMC1786607  PMID: 4637511

Abstract

The influence of the newer, non-barbiturate hypnotics Mandrax (diphenhydramine-methaqualone) and nitrazepam on drug-metabolizing capacity was assessed and compared with the effect of amylobarbitone, a known inducer of drug-metabolizing enzymes. Plasma antipyrine and phenylbutazone half-lives and urinary output of 6β-hydroxycortisol were used as indices. Volunteer subjects were exposed to therapeutic amounts of these agents and, in the case of Mandrax and barbiturates, further studies were carried out in dependent patients.

Mandrax but not nitrazepam increased the rate of drug metabolism, presumably by enzyme induction. The degree of induction was comparable with that produced by hypnotic doses of amylobarbitone. The Mandrax-dependent and barbiturate-dependent patients were the fastest metabolizers studied. It is concluded that drug interactions resulting from interference with drug metabolism are as likely to occur with Mandrax as with barbiturates. On the other hand, it is unlikely that such drug interactions would occur with nitrazepam.

Full text

PDF
322

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B. B., AXELROD J. The fate of antipyrine in man. J Pharmacol Exp Ther. 1950 Jan;98(1):97–104. [PubMed] [Google Scholar]
  2. BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
  3. Ballinger B., Browning M., O'Malley K., Stevenson I. H. Drug-metabolizing capacity in states of drug dependence and withdrawal. Br J Pharmacol. 1972 Aug;45(4):638–643. doi: 10.1111/j.1476-5381.1972.tb08122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ballinger B., O'Malley K., Stevenson I. H., Turnbull M. J. Stimulation of drug metabolism by centrally active drugs. Br J Pharmacol. 1971 Feb;41(2):383P–383P. [PMC free article] [PubMed] [Google Scholar]
  5. Breckenridge A., Orme M. Clinical implications of enzyme induction. Ann N Y Acad Sci. 1971 Jul 6;179:421–431. doi: 10.1111/j.1749-6632.1971.tb46919.x. [DOI] [PubMed] [Google Scholar]
  6. Brooks S. M., Werk E. E., Ackerman S. J., Sullivan I., Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med. 1972 May 25;286(21):1125–1128. doi: 10.1056/NEJM197205252862103. [DOI] [PubMed] [Google Scholar]
  7. Conney A. H., Jacobson M., Schneidman K., Kuntzman R. Induction of liver microsomal cortisol 6beta-hydroxylase by diphenylhydantoin or phenobarbital: an explanation for the increased excretion of 6-hydroxycortisol in humans treated with these drugs. Life Sci. 1965 May;4(10):1091–1098. doi: 10.1016/0024-3205(65)90229-8. [DOI] [PubMed] [Google Scholar]
  8. FEW J. D. A method for the analysis of urinary 17-hydroxycorticosteroids. J Endocrinol. 1961 Mar;22:31–46. doi: 10.1677/joe.0.0220031. [DOI] [PubMed] [Google Scholar]
  9. Kolmodin B., Azarnoff D. L., Sjöqvist F. Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther. 1969 Sep-Oct;10(5):638–642. doi: 10.1002/cpt1969105638. [DOI] [PubMed] [Google Scholar]
  10. MacDonald M. G., Robinson D. S., Sylwester D., Jaffe J. J. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responese in man. Clin Pharmacol Ther. 1969 Jan-Feb;10(1):80–84. doi: 10.1002/cpt196910180. [DOI] [PubMed] [Google Scholar]
  11. O'Malley K., Stevenson I. H., Crooks J. Impairment of human drug metabolism by oral contraceptive steroids. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):552–557. doi: 10.1002/cpt1972134552. [DOI] [PubMed] [Google Scholar]
  12. Poland A., Smith D., Kuntzman R., Jacobson M., Conney A. H. Effect of intensive occupational exposure to DDT on phenylbutazone and cortisol metabolism in human subjects. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):724–732. doi: 10.1002/cpt1970115724. [DOI] [PubMed] [Google Scholar]
  13. Sellers E. M., Koch-Weser J. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci. 1971 Jul 6;179:213–225. doi: 10.1111/j.1749-6632.1971.tb46901.x. [DOI] [PubMed] [Google Scholar]
  14. Thrasher K., Werk E. E., Jr, Choi Y., Sholiton L. J., Meyer W., Olinger C. The measurement, excretion, and source of urinary 6-hydroxycortisol in humans. Steroids. 1969 Nov;14(5):455–468. doi: 10.1016/s0039-128x(69)80040-1. [DOI] [PubMed] [Google Scholar]
  15. Vesell E. S., Ng L., Passananti G. T., Chase T. N. Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet. 1971 Aug 14;2(7720):370–370. doi: 10.1016/s0140-6736(71)90081-x. [DOI] [PubMed] [Google Scholar]
  16. WERK E. E., Jr, MACGEE J., SHOLITON L. J. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest. 1964 Sep;43:1824–1835. doi: 10.1172/JCI105056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Whittaker J. A., Evans D. A. Genetic control of phenylbutazone metabolism in man. Br Med J. 1970 Nov 7;4(5731):323–328. doi: 10.1136/bmj.4.5731.323. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES